General
Preferred name
GEMCITABINE
Synonyms
GEMCITABINE HYDROCHLORIDE ()
Gemzar, LY-188011 ()
LY 188011 hydrochloride ()
LY188011 ()
Gemzar ()
NSC 613327 ()
Gemcitabine HCl ()
Gemcitabine HCl (Gemzar) ()
Gemcitabine (LY-188011) ()
Gemcitabine (LY-188011) HCl ()
LY-188011, NSC 613327 ()
NSC 613327,LY-188011 HCl ()
LY-188011 ()
NSC-613327 ()
Gemcitabine (as hydrochloride) ()
LY188011 HYDROCHLORIDE ()
Infugem ()
LY-188011 HYDROCHLORIDE ()
Gemcitabine-13C,15N2 (hydrochloride) ()
Gemcitabine (Hydrochloride) ()
P&D ID
PD003524
CAS
95058-81-4
103882-84-4
122111-03-9
2757566-59-7
Tags
prodrug
nuisance
natural product
drug
available
Approved by
PMDA
FDA
First approval
1996
Drug Status
approved
Drug indication
Antineoplastic
Solid tumour/cancer
Max Phase
Phase 4
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Gemcitabine is a nucleoside analogue chemotherapeutic. Chemically, the hydrogen atoms on the 2' carbon of deoxycytidine are replaced by fluorine atoms. (GtoPdb)
DESCRIPTION inhibitor of DNA replication; inhibitor of ribonucleotide reductase, thymidylate synthetase, and cytidine monophosphate (UMP-CMP) kinase (Informer Set)
DESCRIPTION Inhibits DNA synthesis and function. Inhibits DNA topoisomerase II (Tocris Bioactive Compound Library)
Cell lines
678
Organisms
10
Compound Sets
31
AdooQ Bioactive Compound Library
A11434
A10423
Axon Medchem Screening Library
3233
Cayman Chemical Bioactives
11690
9003096
22560
ChEMBL Approved Drugs
CHEMBL888
CHEMBL1637
ChEMBL Drugs
CHEMBL888
CHEMBL1637
Concise Guide to Pharmacology 2017/18
4793
Concise Guide to Pharmacology 2019/20
4793
Concise Guide to Pharmacology 2021/22
4793
Concise Guide to Pharmacology 2023/24
4793
Drug Repurposing Hub
DrugBank
DB00441
DrugBank Approved Drugs
DB00441
DrugCentral
1283
DrugCentral Approved Drugs
1283
DrugMAP
DMSE3I7
DrugMAP Approved Drugs
DMSE3I7
Enamine BioReference Compounds
Guide to Pharmacology
4793
Informer Set
411863
LINCS compound set
10252-101
10252-999
NCATS Inxight Approved Drugs
B76N6SBZ8R
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
Nuisance compounds in cellular assays
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
Gemcitabine(Gemzar)
Gemcitabine-Hydrochloride(Gemzar)
TargetMol Bioactive Compound Library
T0251
T6069
The Spectrum Collection
Tocris Bioactive Compound Library
3259
Welcome Trust Cancer Drugs
135
External IDs
100
Properties
(calculated by RDKit )
Molecular Weight
263.07
Hydrogen Bond Acceptors
7
Hydrogen Bond Donors
3
Rotatable Bonds
2
Ring Count
2
Aromatic Ring Count
1
cLogP
-1.29
TPSA
110.6
Fraction CSP3
0.56
Chiral centers
3.0
Largest ring
6.0
QED
0.61
Structural alerts
1
Genotoxic
Nuisance compounds in cellular assays
Related compounds
Custom attributes
(extracted from source data)
Target
CMPK1
RRM1
TYMS
DNA synthesis
CMPK1, RRM1, RRM2, TYMS
DNA synthesis inhibitor
Apoptosis related,Autophagy,DNA/RNA Synthesis,Nucleoside Analog/Antimetabolite
Autophagy,DNA/RNA Synthesis,Nucleoside Analog/Antimetabolite
Compound status
FDA
Pathway
DNA replication
DNA Damage/DNA Repair
Autophagy
Primary Target
DNA, RNA and Protein Synthesis
MOA
DNA/RNA Synthesis
Inhibitor
Ribonucleotide Reductase inhibitor
DNA Damaging Agent
Member status
member
Indication
ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC), pancreatic cancer
Therapeutic Class
Anticancer Agents
Source data